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Abstract
Background: Trastuzumab (Herceptin), an antagonist to the human epidermal growth factor 2
(HER2) receptor significantly decreases the rates of breast cancer recurrence and mortality by
50%. Despite therapeutic benefits, the risk of cardiotoxicity with trastuzumab ranges from 10–15%
when administered sequentially following anthraycline chemotherapy. Little is known about the
utility of cardiac magnetic resonance (CMR) in the assessment of trastuzumab mediated
cardiomyopathy.
Methods and results: Between 2005–2006 inclusive, 160 breast cancer patients were identified
at a single tertiary care oncology centre. Of the total population, 10 patients (mean age 40 ± 8
years) were identified with trastuzumab induced cardiomyopathy, based on a LVEF less than 40%
on serial MUGA or echocardiography. CMR was performed in all patients to determine LV
volumes, systolic function and evidence of late gadolinium enhancement (LGE). At the time of
diagnosis of trastuzumab induced cardiomyopathy, the mean LVEF was 29 ± 4%. Subepicardial linear
LGE was present in the lateral portion of the left ventricles in all 10 patients.
Conclusion: LGE-CMR is a novel way of detecting early changes in the myocardium due to
trastuzumab induced cardiotoxicity.
Introduction
Breast cancer is a major public health concern that affects
1 in 7 women in their lifetime [1]. Anthracyclines are
commonly used in the setting of adjuvant therapy in the
treatment of breast cancer patients. While anthracyclines
significantly improve clinical morbidity and mortality,
there are notable cardiotoxic side effects [2]. Recent
understanding of the biology of breast cancer has lead to
the introduction of a new therapeutic agent, Trastuzumab
(Herceptin), an antagonist to the human epidermal
growth factor 2 (HER2) receptor, which is found in 25%
of breast cancer patients [3]. When added to conventional
anthracycline chemotherapy, trastuzumab significantly
decreases the rates of recurrence and mortality by 50% in
HER-2 positive breast cancer patients [4-6]. Despite thera-
peutic benefits however, the risk of cardiotoxicity with
trastuzumab ranges from 10–15% when administered in
combination with anthracyline therapy [7,8].
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widely used to monitor cardiac dysfunction in breast can-
cer patients. However, with the improvement in both spa-
tial and temporal resolution of cardiac magnetic
resonance (CMR) over the past decade, it has now become
the gold standard for the non-invasive assessment of left
ventricular (LV) systolic dysfunction. Additionally, late
gadolinium enhancement (LGE) can detect myocardial
scarring. Although frequently used in the assessment of
dilated cardiomyopathies secondary to ischemia or myo-
carditis [9], little is known about the utility of CMR in the
assessment of trastuzumab induced cardiomyopathy. We
report a case series of trastuzumab induced myocarditis
characterized by left ventricular dysfunction and focal epi-
cardial LGE using CMR imaging.
Methodology
Patient population
Between 2005–2006 inclusive, 160 breast cancer patients
who received trastuzamab in addition to anthracyline
based adjuvant therapy were identified at a tertiary care
oncology centre. All patients received FEC (5-fluorouracil,
epirubicin and cyclophoshamide) for a total of 6 cycles.
The mean duration between completion of chemotherapy
and initiation of trastuzumab was 2 ± 1 months. Of the
total population, 10 patients were identified with trastu-
zumab induced cardiomyopathy based on LV ejection
fraction less than 40% on either serial MUGA or echocar-
diography. The medical records of all 10 patients were
extensively reviewed for baseline demographic data. The
retrospective study was approved by the local institutional
review board.
Cardiac MRI
CMR was performed on all 10 patients using a 1.5 T scan-
ner (Avanto, Siemens, Erlangen, Germany). Morphologic
images in the cardiac short axis, 4 chamber long axis and
2 chamber long axis planes were acquired using IR-pre-
pared dark blood HASTE sequences (TR 600 ms, TE 26
ms, 6 mm slice thickness, 1.8 mm interslice gap). In the
same planes, cine-CMR was performed using a breath-
hold balanced steady state free precession sequence (True-
FISP, TR 42 ms, TE 1.2 ms, FA 70°, 6 mm slice thickness,
matrix 192 × 174). The cine-CMR short-axis images
encompassed the entire LV from the base to the apex
(stack of 10 sequential short-axis slices; TR 64 ms, TE 1
ms, FA 80°, 8 mm slice thickness, 1.6 mm interslice gap,
matrix 192 × 132) to obtain a left ventricular ejection frac-
tion (LVEF). Late gadolinium enhancement was per-
formed after 10 minutes of 0.2 mmol/kg injection of
Gadolinium (Gd-DTPA, Magnevist, Schering, Germany)
using a T1-weighted IR-prepared multislice TrueFISP
sequence with magnitude and phase sensitive reconstruc-
tion. Images were acquired sequentially in the short axis,
followed by horizontal and vertical long axis images (TR
700 ms, TE 1.0 ms, FA 40°, 8 mm slice thickness, 1.6 mm
interslice gap, matrix 192 × 144).
Results
The total population included 10 patients (mean age 40 ±
8 years, range 27 to 56 years) with normal LVEF at base-
line and preserved systolic function following administra-
tion of anthracycline based chemotherapy using serial
MUGA scans (Table 1). Cardiovascular risk factors, dose
and frequency of chemotherapy, concomitant use of radi-
ation therapy, and duration of trastuzumab therapy (3–5
months) were similar in the entire patient cohort (Table
1).
At the time of diagnosis of trastuzumab induced cardio-
myopathy, the left ventricular cavities were dilated with
moderate to severe global LV systolic dysfunction on CMR
(Table 2). The mean LVEF was for the total population
was 29 ± 4% (Table 2). Subepicardial linear LGE was
present in the lateral portion of the left ventricles in all 10
patients suggesting the presence of trastuzumab induced
myocarditis (Figure 1).
Following the discontinuation of trastuzumab, 6 patients
have recovered normal LV systolic function, while 4
Table 1: Clinical Characteristics of Patient Population (n = 10)
Case No. Age CV risk Radiotherapy Baseline LVEF (%) Post Chemothx LVEF (%) Trastuzumab Duration
1 33 None Yes 55 52 4 months
2 41 HTN Yes 60 58 5 months
3 27 None Yes 54 56 4 months
4 39 None Yes 65 62 3 months
5 44 Lipids Yes 58 55 4 months
6 38 None Yes 56 52 5 months
7 56 HTN Yes 60 62 3 months
8 45 HTN Yes 54 55 4 months
9 32 None Yes 55 52 5 months
10 40 HTN Yes 60 58 4 months
CV, cardiovascular; LVEF, left ventricular ejection fraction; chemothx, chemotherapy; HTN, hypertension.Page 2 of 4
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lowup, despite appropriate heart failure medications
including ACE inhibition and beta blockade (Table 2).
The linear LGE-CMR findings persisted at 6 months in all
patients despite improvement in LVEF in over half of the
patients.
Discussion
An increasing understanding of the biology of breast can-
cer has lead to the identification of novel therapeutic tar-
gets. The HER2 receptor is a member of the epidermal
growth factor receptor family of transmembrane tyrosine
kinases and is normally involved in the regulation of cell
proliferation. Increased expression of HER2 is detected in
25–30% of breast cancers and is associated with poorly
differentiated tumors with a high proliferative rate, posi-
tive axially lymph nodes and decreased expression of
estrogen and progesterone receptors [3]. These character-
istics are associated with an increased risk of disease recur-
rence and death due to breast cancer [3].
Trastuzumab (Herceptin) is a relatively new chimerized
monoclonal antibody that targets the extracellular por-
tion of the HER2 membrane protein. Previous studies
have demonstrated that trastuzumab provides considera-
ble therapeutic benefits, when added to conventional
anthracycline chemotherapy, in decreasing the rates of
disease recurrence and death in HER2 overexpressed met-
astatic breast cancers [4-6]. Despite its therapeutic benefit,
trastuzumab is cardiotoxic with a 5% prevalence of cardi-
omyopathy when used as monotherapy and 10–15%
prevalence of cardiomyopathy when used in combination
with anthracyclines [7,8].
Various theories have been suggested regarding the possi-
ble pathogenetic origin of trastuzumab induced cardio-
myopathy. These include potentiation of anthracycline
induced cardiotoxicity and immune mediated destruction
of cardiomyocytes [10]. There is increasing evidence as
well supporting a direct toxic effect of HER2 blockade on
the myocardial tissue. HER2 signaling appears to play an
important role in the embryonic cardiac development and
cardioprotection; the blockade of this pathway by trastu-
zumab can also lead to myocardial inflammation and
damage [11].
The use of CMR for the non-invasive characterization of
trastuzumab induced myocarditis is novel. Whereas CMR
has become the standard diagnostic test in the evaluation
of suspected myocarditis [9,12], to date, there are no
reports in the literature describing the utility of LGE for
the diagnosis of trastuzumab induced cardiomyopathy.
The current report demonstrated the common finding of
LGE of the subepicardial lateral wall in all patients, which
may be a typical distribution and location of myocarditis
Short axis phase sensitive reconstructed IR-TrueFISP image t rough the mid-v tricl demonstra s subepicardial linear late gadoliniu  enhancement (arrow) in the lateral wa l of apatient w o ha r ce v d TrastuzumabFigure 1
Short axis phase sensitive reconstructed IR-TrueFISP image 
through the mid-ventricle demonstrates subepicardial linear 
late gadolinium enhancement (arrow) in the lateral wall of a 
patient who had received Trastuzumab.
Table 2: CMR findings of patient population (n = 10)
Case No. Age LVEF (%) Delayed enhancement Medical treatment 6 month f/u LVEF (%)
1 33 32 Lateral, septal ACEI, beta blockers 55
2 41 28 Lateral ACEI, beta blockers 60
3 27 30 Lateral ACEI, beta blockers 40
4 39 25 Lateral ACEI, beta blockers 65
5 44 35 Lateral, septal ACEI, beta blockers 60
6 38 30 Lateral ACEI, beta blockers 40
7 56 25 Lateral ACEI, beta blockers 30
8 45 24 Lateral ACEI, beta blockers 55
9 32 30 Lateral ACEI, beta blockers 35
10 40 34 Lateral ACEI, beta blockers 58
LVEF, left ventricular ejection fraction; ACEI, angiotensin converting enzyme inhibitor.Page 3 of 4
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in this drug induced cardiomyopathy. Although 6 patients
recovered LVEF by CMR with appropriate therapy for
CHF, it is of interest that the LGE findings persisted up to
6 months in all patients, suggesting persistent injury to the
myocardium. A limitation of the current retrospective
study however is the small number of individuals. A larger
prospective series may enable us to make more substan-
tive conclusions regarding the role of LGE-CMR in the
diagnosis and prognosis of this patient population.
Conclusion
Late gadolinium enhancement using CMR is a novel way
of detecting early changes in the myocardium due to tras-
tuzumab induced cardiotoxicity. Future studies are
required to validate identification of positive delayed
enhancement using CMR as a subclinical marker for
future LV dysfunction in this select population. Early
detection of LV dysfunction using LGE-CMR may allow
one to adjust treatment with trastuzumab prior to the
development of irreversible heart failure.
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